An investigator-initiated clinical study of GPN02006 developed by Grand Pharmaceutical Group (HKG:0512) in cooperation with two other parties for the diagnosis of hepatocellular carcinoma recently achieved a milestone breakthrough, a Tuesday Hong Kong bourse filing said.
The clinical results showed the drug exhibits "excellent" safety and imaging efficacy, as well as high-quality imaging 30 minutes post administration.
The drug was developed in cooperation with Wuhan Ruidifu Biotechnology and JECHO Biopharmaceuticals.